Clay Siegall, Seattle Genetics & Cancer Research

The fight against cancer has been waging for over a century. This deadly disease can manifest its ugly head from a number of internal organs such as the liver, the lungs and the prostate. Unfortunately, millions of people have lost their lives thanks to this disease, but the 21st century is yielding better results. Thanks to all of the advancements in technology, cancer has been rocked with a strong blow. These technologies have helped to produce cancer-fighting medications that are much more effective. Dr. Clay Siegall stands at the forefront of this progressive movement, and he has a long history of success. Dr. Siegall is a man of many acts. Many of his peers refer to him as being a doctor, a businessman, a philanthropist and an entrepreneur.

Dr. Siegall is the CEO of Seattle Genetics. This oncology company studies and manipulates human antibodies. Seattle Genetics’ drug portfolio is immense, and it has at least 20 advanced drugs in its pipeline. Out of the 20 drugs, four are 100 percent ready to hit the market. “It takes time before a drug can get FDA-approved,” said Siegall. As of now, Seattle Genetics is earning huge profits from its flagship drug. ADCETRIS has helped to revolutionize the industry in more ways than one. This targeted-cancer treatment is being used all around the globe, and it’s saving lives. Dr. Siegall has worked hard at securing multiple licensing deals with some of the top pharmaceutical companies in today’s society.

This extraordinary man currently holds at least 15 patents, and he has written up to 70 publications. What more could anyone ever ask for from a doctor/scientist? To be perfectly honest, Dr. Clay Siegall is definitely doing a fantastic job to better mankind, but bigger things are certainly on the horizon.

Leave a Reply

Your email address will not be published. Required fields are marked *